DMN:FRA
Diamyd Medical AB
0,064 €
arrow_upward
+1,92%(+0,0012) 1D
20-ноя., 08:04:51 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
0,06 €
High
0,06 €
Low
0,06 €
Mkt. cap
135,11 млн
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
Open
0,06 €
High
0,06 €
Low
0,06 €
Mkt. cap
135,11 млн
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
News stories
From web sources and news partners
marketscreener.com
·
51 мүнөт мурун
Societe Generale sees S&P 500 ending 2027 at 8,500 on AI, earnings support
Traders Union
·
24 мүнөт мурун
Mohamed A. El-Erian: S&P 500 may face longest losing streak since 2020 as 10-year Treasury yield falls
24/7 Wall St.
·
23 мүнөт мурун
The S&P 500 Just Had Its Biggest Reversal Since March 2020
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB